Enhancing FibroScan® liver disease assessment with biological markers
A single biomarker cannot answer to all questions.
With FibroScan®-based scores, you can combine FibroScan® results with other parameters to get the best performance and a better identification of your patients.
Scores by echosens are available on myFibroScan application.
Suspected MASLD patients
MASH + NAS≥4 + F≥2
Screening for clinical trial and identifying at-risk MASH patients (Formerly NASH)
FibroScan® results (LSM by VCTE™ & CAP™) + laboratory parameter (AST)
Suspected MASLD patients
F≥3
Identifying MASLD patients with advanced fibrosis and predicting risk of complications
LSM by VCTE™ + Clinical parameters (AST, ALT, Platelets, Presence of Diabetes, Age and Gender)
Suspected MASLD patients
F4
Identifying MASLD patients with cirrhosis that need to be screen for HCC
LSM by VCTE™ + Clinical parameters (AST, ALT, Platelets, Presence of Diabetes and Gender)
The non-invasive gold standard solution for comprehensive management of liver health
Cloud-based solution to assist clinicians in providing comprehensive liver care.
Your everyday FibroScan® companion – free application
Fast™ is an in vitro diagnostic medical device according to directive 98/79/EC. Fast™ calculator is a tool for clinicians, computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of MASLD as being at risk for active fibrotic MASH (MASH+NAS≥4+F≥2). Agile 3+ and Agile 4 are class I medical devices according to Directive 93/42/EEC. Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of MASLD as having advanced fibrosis. Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of MASLD as having cirhhosis.
These scores were developed based on pools of cohorts and are published in peer-reviewed literature. They are presented as educational services intended for licensed healthcare professionals. While these scores are about specific medical and health issues, they are not substitutes for or replacements of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
FibroScan®
